Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
October 31, 2023 09:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
October 31, 2023 09:00 ET
|
Akoya Biosciences, Inc.
Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya’s spatial phenotyping solutions will also exhibit...
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
October 30, 2023 06:41 ET
|
ImCheck Therapeutics SAS
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting Marseille, France, October 30, 2023 – ImCheck...
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
October 23, 2023 03:00 ET
|
Medigene AG
Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell...
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 28, 2023 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 15:15 ET
|
GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
November 10, 2022 09:40 ET
|
invIOs GmbH
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a...
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 10, 2022 09:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Mendus AB: Mendus presenterar data under SITC 2022 som visar DCOne-plattformens potential att expandera mördarceller (NK) för terapeutiska ändamål
November 08, 2022 02:00 ET
|
Mendus AB
STIMULERING MED DCONE-CELLER LEDER TILL SELEKTIV OCH STARK >200-FALDIG MEDIANEXPANSION AV NK CELLER MED IMMUNOLOGISKT MINNE Mendus AB (“Mendus”; IMMU.ST), ett bioläkemedelsföretag fokuserat på...
Mendus AB: Mendus to present data at SITC 2022 demonstrating the potential of the DCOne platform to expand memory NK cells for therapeutic purposes
November 08, 2022 02:00 ET
|
Mendus AB
STIMULATION WITH DCONE CELLS LEADS TO SELECTIVE AND STRONG >200-FOLD MEDIAN EXPANSION OF MEMORY NK CELLS Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...